Diverse nucleosome site-selectivity among histone deacetylase complexes

  1. Zhipeng A Wang
  2. Christopher J Millard
  3. Chia-Liang Lin
  4. Jennifer E Gurnett
  5. Mingxuan Wu
  6. Kwangwoon Lee
  7. Louise Fairall
  8. John W R Schwabe  Is a corresponding author
  9. Philip A Cole  Is a corresponding author
  1. Brigham and Women's Hospital, United States
  2. University of Leicester, United Kingdom
  3. Harvard Medical School, United States

Abstract

Histone acetylation regulates chromatin structure and gene expression and is removed by histone deacetylases (HDACs). HDACs are commonly found in various protein complexes to confer distinct cellular functions, but how the multi-subunit complexes influence deacetylase activities and site-selectivities in chromatin is poorly understood. Previously we reported the results of studies on the HDAC1 containing CoREST complex and acetylated nucleosome substrates which revealed a notable preference for deacetylation of histone H3 acetyl-Lys9 vs. acetyl-Lys14 (M. Wu et al, 2018). Here we analyze the enzymatic properties of five class I HDAC complexes: CoREST, NuRD, Sin3B, MiDAC and SMRT with site-specific acetylated nucleosome substrates. Our results demonstrate that these HDAC complexes show a wide variety of deacetylase rates in a site-selective manner. A Gly13 in the histone H3 tail is responsible for a sharp reduction in deacetylase activity of the CoREST complex for H3K14ac. These studies provide a framework for connecting enzymatic and biological functions of specific HDAC complexes.

Data availability

Data has been uploaded to Dryad under the doi:10.5061/dryad.x0k6djhgc

The following data sets were generated

Article and author information

Author details

  1. Zhipeng A Wang

    Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5693-7359
  2. Christopher J Millard

    Leicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, United Kingdom
    Competing interests
    No competing interests declared.
  3. Chia-Liang Lin

    Leicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, United Kingdom
    Competing interests
    No competing interests declared.
  4. Jennifer E Gurnett

    Leicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, United Kingdom
    Competing interests
    No competing interests declared.
  5. Mingxuan Wu

    Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  6. Kwangwoon Lee

    Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  7. Louise Fairall

    Leicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, United Kingdom
    Competing interests
    No competing interests declared.
  8. John W R Schwabe

    Leicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, United Kingdom
    For correspondence
    john.schwabe@le.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2865-4383
  9. Philip A Cole

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    For correspondence
    pacole@bwh.harvard.edu
    Competing interests
    Philip A Cole, Senior editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6873-7824

Funding

NIH (GM62437)

  • Philip A Cole

Leukemia and Lymphoma Society (SCOR)

  • Philip A Cole

Wellcome Trust Senior Investigator Award (100237/Z/12/Z)

  • John W R Schwabe

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,006
    views
  • 660
    downloads
  • 44
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zhipeng A Wang
  2. Christopher J Millard
  3. Chia-Liang Lin
  4. Jennifer E Gurnett
  5. Mingxuan Wu
  6. Kwangwoon Lee
  7. Louise Fairall
  8. John W R Schwabe
  9. Philip A Cole
(2020)
Diverse nucleosome site-selectivity among histone deacetylase complexes
eLife 9:e57663.
https://doi.org/10.7554/eLife.57663

Share this article

https://doi.org/10.7554/eLife.57663

Further reading

    1. Biochemistry and Chemical Biology
    Vladimir Khayenko, Cihan Makbul ... Hans Michael Maric
    Research Article

    The hepatitis B virus (HBV) infection is a major global health problem, with chronic infection leading to liver complications and high death toll. Current treatments, such as nucleos(t)ide analogs and interferon-α, effectively suppress viral replication but rarely cure the infection. To address this, new antivirals targeting different components of the HBV molecular machinery are being developed. Here we investigated the hepatitis B core protein (HBc) that forms the viral capsids and plays a vital role in the HBV life cycle. We explored two distinct binding pockets on the HBV capsid: the central hydrophobic pocket of HBc-dimers and the pocket at the tips of capsid spikes. We synthesized a geranyl dimer that binds to the central pocket with micromolar affinity, and dimeric peptides that bind the spike-tip pocket with sub-micromolar affinity. Cryo-electron microscopy further confirmed the binding of peptide dimers to the capsid spike tips and their capsid-aggregating properties. Finally, we show that the peptide dimers induce HBc aggregation in vitro and in living cells. Our findings highlight two tractable sites within the HBV capsid and provide an alternative strategy to affect HBV capsids.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Assmaa Elsheikh, Camden M Driggers ... Show-Ling Shyng
    Research Article

    Pancreatic KATP channel trafficking defects underlie congenital hyperinsulinism (CHI) cases unresponsive to the KATP channel opener diazoxide, the mainstay medical therapy for CHI. Current clinically used KATP channel inhibitors have been shown to act as pharmacochaperones and restore surface expression of trafficking mutants; however, their therapeutic utility for KATP trafficking-impaired CHI is hindered by high affinity binding, which limits functional recovery of rescued channels. Recent structural studies of KATP channels employing cryo-electron microscopy (cryoEM) have revealed a promiscuous pocket where several known KATP pharmacochaperones bind. The structural knowledge provides a framework for discovering KATP channel pharmacochaperones with desired reversible inhibitory effects to permit functional recovery of rescued channels. Using an AI-based virtual screening technology AtomNet followed by functional validation, we identified a novel compound, termed Aekatperone, which exhibits chaperoning effects on KATP channel trafficking mutations. Aekatperone reversibly inhibits KATP channel activity with a half-maximal inhibitory concentration (IC50) ~9 μM. Mutant channels rescued to the cell surface by Aekatperone showed functional recovery upon washout of the compound. CryoEM structure of KATP bound to Aekatperone revealed distinct binding features compared to known high affinity inhibitor pharmacochaperones. Our findings unveil a KATP pharmacochaperone enabling functional recovery of rescued channels as a promising therapeutic for CHI caused by KATP trafficking defects.